Agency Information Collection Activities; Proposed Collection; Comment Request; Evaluation of the Food and Drug Administration's General Market Youth Tobacco Prevention Campaigns, 37546-37548 [2013-14809]

Download as PDF 37546 Federal Register / Vol. 78, No. 120 / Friday, June 21, 2013 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Food and Drug Administration [Docket No. FDA–2013–N–0717] [Docket No. FDA–2012–N–0306] Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Administrative Detention and Banned Medical Devices AGENCY: Food and Drug Administration, HHS. ACTION: AGENCY: FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50– 400B, Rockville, MD 20850, 301–796– 5156, Daniel.Gittleson@fda.hhs.gov. On February 8, 2013, the Agency submitted a proposed collection of information entitled ‘‘Administrative Detention and Banned Medical Devices’’ to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0114. The approval expires on April 30, 2016. A copy of the supporting statement for this information collection is available on the Internet at https:// www.reginfo.gov/public/do/PRAMain. SUPPLEMENTARY INFORMATION: Dated: June 17, 2013. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2013–14810 Filed 6–20–13; 8:45 am] BILLING CODE 4160–01–P 18:32 Jun 20, 2013 Notice. The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish a notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Evaluation of FDA’s General Market Youth Tobacco Prevention Campaigns. DATES: Submit either electronic or written comments on the collection of information by August 20, 2013. ADDRESSES: Submit electronic comments on the collection of information to https:// www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50– 400B, Rockville, MD 20850, 301–796– 5156, daniel.gittleson@fda.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ‘‘Administrative Detention and Banned Medical Devices’’ has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. VerDate Mar<15>2010 Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: TKELLEY on DSK3SPTVN1PROD with NOTICES Agency Information Collection Activities; Proposed Collection; Comment Request; Evaluation of the Food and Drug Administration’s General Market Youth Tobacco Prevention Campaigns Jkt 229001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Evaluation of FDA’s General Market Youth Tobacco Prevention Campaigns (OMB Control Number—0910—New) The 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) (Pub. L. 111–31) amends the Federal Food, Drug, and Cosmetic Act (the FD&C Act) to grant FDA authority to regulate the manufacture, marketing, and distribution of tobacco products to protect public health and to reduce tobacco use by minors. Section 1003(d)(2)(D) of the FD&C Act (21 U.S.C. 393(d)(2)(D)) supports the development and implementation of FDA public education campaigns related to tobacco use. Accordingly, FDA is currently developing and implementing youth-targeted public education campaigns to help prevent tobacco use among youth and thereby reduce the public health burden of tobacco. The campaigns will feature televised advertisements along with complementary ads on radio, on the Internet, in print, and through other forms of media. In support of the provisions of the Tobacco Control Act that require FDA to protect the public health and to reduce tobacco use by minors, FDA requests OMB approval to collect information needed to evaluate FDA’s general market youth tobacco prevention campaigns. Comprehensive evaluation of FDA’s public education campaigns is needed to ensure campaign messages are effectively received, understood, and accepted by those for whom they are intended. Evaluation is an essential organizational practice in public health E:\FR\FM\21JNN1.SGM 21JNN1 Federal Register / Vol. 78, No. 120 / Friday, June 21, 2013 / Notices and a systematic way to account for and improve public health actions. FDA plans to conduct two studies to evaluate the effectiveness of its youth tobacco prevention campaigns: (1) An outcome evaluation study and (2) a media tracking survey. The timing of these studies will be designed to follow the multiple, discrete waves of media advertising planned for the campaigns. • Outcome Evaluation Study The outcome evaluation study consists of an initial baseline survey of youth aged 11 to 16 before the campaigns launch. The baseline will be followed by three longitudinal followup surveys of the same youth at approximate 8 month intervals after the campaigns launch. As the cohort will be aging over this time period, the data collected throughout the study will reflect information from youth aged 11 to 18. Information will be collected about youth awareness of and exposure to campaign advertisements and about youth knowledge, attitudes, and beliefs related to tobacco use. In addition, the surveys will measure tobacco use susceptibility and current use. Information will also be collected on demographic variables including age, sex, race/ethnicity, grade level, and primary language. Finally, a baseline survey will also be conducted with the parent or legal guardian of each youth baseline survey participant in order to collect data on household characteristics and media use. • Media Tracking Survey The media tracking survey consists of assessments of youth aged 13 to 18 conducted at 4 months, 12 months, and 20 months postlaunch. The tracking survey will assess awareness of the campaigns and receptivity to campaign messages. These data will provide critical evaluation feedback to the campaigns and will be conducted with sufficient frequency to match the cyclical patterns of media advertising and variation in exposure to allow for mid-campaign refinements. All information will be collected through in-person and Web-based questionnaires. Youth respondents will be recruited from two sources: (1) A probability sample drawn from 90 U.S. media markets gathered using an address-based postal mail sampling of U.S. households for the outcome evaluation study and (2) an Internet panel for the media tracking survey. Participation in the studies is voluntary. The information collected is necessary to inform FDA’s efforts and measure the effectiveness and public health impact of the campaigns. Data from the media tracking survey will be used to estimate awareness of and exposure to the campaigns among youth nationally as well as among youth in geographic areas targeted by the campaign. Data from the outcome evaluation study will be used to examine statistical associations between exposure to the campaigns and subsequent changes in specific outcomes of interest, which will include knowledge, attitudes, beliefs, and intentions related to tobacco use, as well as behavioral outcomes including tobacco use. FDA’s burden estimate is based on prior experience with in-person and Internet panel studies similar to the Agency’s plan presented in this document. To obtain the target number of completed surveys (‘‘completes’’) for the outcome evaluation study, 55,695 youth respondents and their parent or legal guardian will be contacted through a screening and consent process. The estimated burden per response is 5 minutes (0.083), for a total of 4,623 hours. An estimated 12,940 youth will 37547 complete the Youth Baseline Questionnaire in order to yield 10,352 completes at the first followup, 8,281 completes at the second followup, and 6,625 completes at the third followup survey waves. The estimated burden per response is 30 minutes (0.5) for the baseline questionnaire, for a total of 6,470 hours. The estimated burden per response is 30 minutes (0.5) for each followup questionnaire, for a total of 5,176 burden hours for the first Followup Questionnaire, 4,141 hours for the second Followup Questionnaire, and 3,313 hours for the third Followup Questionnaire. The parent or legal guardian of youth recruited to complete the Youth Baseline Questionnaire will also complete a Parent Baseline Questionnaire with an estimate burden per response of 10 minutes (0.17), for a total of 2,200 hours. To obtain the target number of completes for the media tracking survey, 40,000 respondents will be contacted for each survey wave through an online invitation. The estimated burden per response is 2 minutes (0.03), for a total of 1,200 hours for the first Media Tracking Screener, 1,200 hours for the second Media Tracking Screener, and 1,200 hours for the third Media Tracking Screener. An estimated 4,000 youth will be recruited to complete each of the three waves of the media tracking survey. The estimated burden per response is 30 minutes for each questionnaire, for a total of 2,000 hours for the first Media Tracking Questionnaire, 2,000 hours for the second Media Tracking Questionnaire, and 2,000 hours for the third Media Tracking Questionnaire. The target number of completed campaign questionnaires for all respondents is 238,833. The total estimated burden is 35,523 hours. OMB approval is requested for 3 years. TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Activity General Population ............ Screener and Consent Process (Youth and Parent). Outcome Evaluation Youth Baseline Questionnaire. Outcome Evaluation Youth 1st Followup Questionnaire. Outcome Evaluation Youth 2nd Followup Questionnaire. Outcome Evaluation Youth 3rd Followup Questionnaire. TKELLEY on DSK3SPTVN1PROD with NOTICES Youth aged 11–18 in the United States. VerDate Mar<15>2010 18:32 Jun 20, 2013 Jkt 229001 PO 00000 Number of responses per respondent Number of respondents Type of respondent Frm 00044 Total annual responses Average burden per response Total hours 55,695 1 55,695 0.083 (5 min.) ... 4,623 12,940 1 12,940 0.5 (30 min.) ..... 6,470 10,352 1 10,352 0.5 (30 min.) ..... 5,176 8,281 1 8,281 0.5 (30 min.) ..... 4,141 6,625 1 6,625 0.5 (30 min.) ..... 3,313 Fmt 4703 Sfmt 4703 E:\FR\FM\21JNN1.SGM 21JNN1 37548 Federal Register / Vol. 78, No. 120 / Friday, June 21, 2013 / Notices TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Type of respondent Parent of Youth Baseline Survey Participants. Youth aged 13–18 in the United States. Total ........................... 1 There Outcome Evaluation Parent Baseline Questionnaire. Screener ............................ 1st Media Tracking Questionnaire. Screener ............................ 2nd Media Tracking Questionnaire. Screener ............................ 3rd Media Tracking Questionnaire. ........................................... BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0719] Agency Information Collection Activities: Proposed Collection; Comment Request; Guidance for Industry on Planning for the Effects of High Absenteeism To Ensure Availability of Medically Necessary Drug Products Food and Drug Administration, HHS. Notice. The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection in the guidance on planning for the effects of high absenteeism to ensure availability of medically necessary drug products. DATES: Submit either electronic or written comments on the collection of information by August 20, 2013. SUMMARY: TKELLEY on DSK3SPTVN1PROD with NOTICES Average burden per response Total hours 12,940 1 12,940 0.17 (10 min.) ... 2,200 40,000 4,000 1 1 40,000 4,000 0.03 (2 min.) ..... 0.5 (30 min.) ..... 1,200 2,000 40,000 4,000 ........................ 1 40,000 4,000 0.03 (2 min.) ..... 0.5 (30 min.) ..... 1,200 2,000 40,000 4,000 1 1 40,000 4,000 0.03 (2 min.) ..... 0.5 (30 min.) ..... 1,200 2,000 238,833 ........................ ........................ ........................... 35,523 VerDate Mar<15>2010 18:32 Jun 20, 2013 Jkt 229001 Submit electronic comments on the collection of information to https:// www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane., Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., P150– 400B, Rockville, MD 20850, 301–796– 7726, Ila.mizrachi@fda.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance ADDRESSES: [FR Doc. 2013–14809 Filed 6–20–13; 8:45 am] ACTION: Total annual responses are no capital costs or operating and maintenance costs associated with this collection of information. Dated: June 17, 2013. Leslie Kux, Assistant Commissioner for Policy. AGENCY: Number of responses per respondent Number of respondents Activity PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Guidance for Industry on Planning for the Effects of High Absenteeism To Ensure Availability of Medically Necessary Drug Products—(OMB Control Number 0910–0675)—Extension The guidance recommends that manufacturers of drug and therapeutic biological products and manufacturers of raw materials and components used in those products develop a written Emergency Plan (Plan) for maintaining an adequate supply of medically necessary drug products (MNPs) during an emergency that results in high employee absenteeism. The guidance discusses the issues that should be covered by the Plan, such as: (1) Identifying a person or position title (as well as two designated alternates) with the authority to activate and deactivate the Plan and make decisions during the emergency; (2) prioritizing the manufacturer’s drug products based on medical necessity; (3) identifying actions that should be taken prior to an anticipated period of high absenteeism; (4) identifying criteria for activating the Plan; (5) performing quality risk assessments to determine which manufacturing activities may be reduced to enable the company to meet E:\FR\FM\21JNN1.SGM 21JNN1

Agencies

[Federal Register Volume 78, Number 120 (Friday, June 21, 2013)]
[Notices]
[Pages 37546-37548]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14809]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0717]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Evaluation of the Food and Drug Administration's
General Market Youth Tobacco Prevention Campaigns

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish a notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on the Evaluation of FDA's General Market
Youth Tobacco Prevention Campaigns.

DATES: Submit either electronic or written comments on the collection
of information by August 20, 2013.

ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-5156,
daniel.gittleson@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Evaluation of FDA's General Market Youth Tobacco Prevention Campaigns
(OMB Control Number--0910--New)

The 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco
Control Act) (Pub. L. 111-31) amends the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) to grant FDA authority to regulate the
manufacture, marketing, and distribution of tobacco products to protect
public health and to reduce tobacco use by minors. Section
1003(d)(2)(D) of the FD&C Act (21 U.S.C. 393(d)(2)(D)) supports the
development and implementation of FDA public education campaigns
related to tobacco use. Accordingly, FDA is currently developing and
implementing youth-targeted public education campaigns to help prevent
tobacco use among youth and thereby reduce the public health burden of
tobacco. The campaigns will feature televised advertisements along with
complementary ads on radio, on the Internet, in print, and through
other forms of media.
In support of the provisions of the Tobacco Control Act that
require FDA to protect the public health and to reduce tobacco use by
minors, FDA requests OMB approval to collect information needed to
evaluate FDA's general market youth tobacco prevention campaigns.
Comprehensive evaluation of FDA's public education campaigns is needed
to ensure campaign messages are effectively received, understood, and
accepted by those for whom they are intended. Evaluation is an
essential organizational practice in public health

[[Page 37547]]

and a systematic way to account for and improve public health actions.
FDA plans to conduct two studies to evaluate the effectiveness of
its youth tobacco prevention campaigns: (1) An outcome evaluation study
and (2) a media tracking survey. The timing of these studies will be
designed to follow the multiple, discrete waves of media advertising
planned for the campaigns.

Outcome Evaluation Study

The outcome evaluation study consists of an initial baseline survey
of youth aged 11 to 16 before the campaigns launch. The baseline will
be followed by three longitudinal followup surveys of the same youth at
approximate 8 month intervals after the campaigns launch. As the cohort
will be aging over this time period, the data collected throughout the
study will reflect information from youth aged 11 to 18. Information
will be collected about youth awareness of and exposure to campaign
advertisements and about youth knowledge, attitudes, and beliefs
related to tobacco use. In addition, the surveys will measure tobacco
use susceptibility and current use. Information will also be collected
on demographic variables including age, sex, race/ethnicity, grade
level, and primary language. Finally, a baseline survey will also be
conducted with the parent or legal guardian of each youth baseline
survey participant in order to collect data on household
characteristics and media use.

Media Tracking Survey

The media tracking survey consists of assessments of youth aged 13
to 18 conducted at 4 months, 12 months, and 20 months postlaunch. The
tracking survey will assess awareness of the campaigns and receptivity
to campaign messages. These data will provide critical evaluation
feedback to the campaigns and will be conducted with sufficient
frequency to match the cyclical patterns of media advertising and
variation in exposure to allow for mid-campaign refinements.
All information will be collected through in-person and Web-based
questionnaires. Youth respondents will be recruited from two sources:
(1) A probability sample drawn from 90 U.S. media markets gathered
using an address-based postal mail sampling of U.S. households for the
outcome evaluation study and (2) an Internet panel for the media
tracking survey. Participation in the studies is voluntary.
The information collected is necessary to inform FDA's efforts and
measure the effectiveness and public health impact of the campaigns.
Data from the media tracking survey will be used to estimate awareness
of and exposure to the campaigns among youth nationally as well as
among youth in geographic areas targeted by the campaign. Data from the
outcome evaluation study will be used to examine statistical
associations between exposure to the campaigns and subsequent changes
in specific outcomes of interest, which will include knowledge,
attitudes, beliefs, and intentions related to tobacco use, as well as
behavioral outcomes including tobacco use.
FDA's burden estimate is based on prior experience with in-person
and Internet panel studies similar to the Agency's plan presented in
this document. To obtain the target number of completed surveys
(``completes'') for the outcome evaluation study, 55,695 youth
respondents and their parent or legal guardian will be contacted
through a screening and consent process. The estimated burden per
response is 5 minutes (0.083), for a total of 4,623 hours. An estimated
12,940 youth will complete the Youth Baseline Questionnaire in order to
yield 10,352 completes at the first followup, 8,281 completes at the
second followup, and 6,625 completes at the third followup survey
waves. The estimated burden per response is 30 minutes (0.5) for the
baseline questionnaire, for a total of 6,470 hours. The estimated
burden per response is 30 minutes (0.5) for each followup
questionnaire, for a total of 5,176 burden hours for the first Followup
Questionnaire, 4,141 hours for the second Followup Questionnaire, and
3,313 hours for the third Followup Questionnaire. The parent or legal
guardian of youth recruited to complete the Youth Baseline
Questionnaire will also complete a Parent Baseline Questionnaire with
an estimate burden per response of 10 minutes (0.17), for a total of
2,200 hours.
To obtain the target number of completes for the media tracking
survey, 40,000 respondents will be contacted for each survey wave
through an online invitation. The estimated burden per response is 2
minutes (0.03), for a total of 1,200 hours for the first Media Tracking
Screener, 1,200 hours for the second Media Tracking Screener, and 1,200
hours for the third Media Tracking Screener. An estimated 4,000 youth
will be recruited to complete each of the three waves of the media
tracking survey. The estimated burden per response is 30 minutes for
each questionnaire, for a total of 2,000 hours for the first Media
Tracking Questionnaire, 2,000 hours for the second Media Tracking
Questionnaire, and 2,000 hours for the third Media Tracking
Questionnaire.
The target number of completed campaign questionnaires for all
respondents is 238,833. The total estimated burden is 35,523 hours. OMB
approval is requested for 3 years.

Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Type of respondent Activity Number of responses per Total annual Average burden per response Total hours
respondents respondent responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
General Population................. Screener and Consent 55,695 1 55,695 0.083 (5 min.)............. 4,623
Process (Youth and
Parent).
Youth aged 11-18 in the United Outcome Evaluation 12,940 1 12,940 0.5 (30 min.).............. 6,470
States. Youth Baseline
Questionnaire.
Outcome Evaluation 10,352 1 10,352 0.5 (30 min.).............. 5,176
Youth 1st Followup
Questionnaire.
Outcome Evaluation 8,281 1 8,281 0.5 (30 min.).............. 4,141
Youth 2nd Followup
Questionnaire.
Outcome Evaluation 6,625 1 6,625 0.5 (30 min.).............. 3,313
Youth 3rd Followup
Questionnaire.

[[Page 37548]]

Parent of Youth Baseline Survey Outcome Evaluation 12,940 1 12,940 0.17 (10 min.)............. 2,200
Participants. Parent Baseline
Questionnaire.
Youth aged 13-18 in the United Screener.............. 40,000 1 40,000 0.03 (2 min.).............. 1,200
States. 1st Media Tracking 4,000 1 4,000 0.5 (30 min.).............. 2,000
Questionnaire.
Screener.............. 40,000 .............. 40,000 0.03 (2 min.).............. 1,200
2nd Media Tracking 4,000 1 4,000 0.5 (30 min.).............. 2,000
Questionnaire.
Screener.............. 40,000 1 40,000 0.03 (2 min.).............. 1,200
3rd Media Tracking 4,000 1 4,000 0.5 (30 min.).............. 2,000
Questionnaire.
--------------------------------------------------------------------------------------------------------------------
Total.......................... ...................... 238,833 .............. .............. ........................... 35,523
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: June 17, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-14809 Filed 6-20-13; 8:45 am]
BILLING CODE 4160-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.